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ABSTRACT 33 
Aim. – To characterize the urinary metabolomic fingerprint and multi-metabolite signature associated 34 
with type 2 diabetes (T2D), and to classify the population into metabotypes related to T2D. Methods. 35 
– A metabolomics analysis using the 1H-NMR-based, non-targeted metabolomic approach was 36 
conducted to determine the urinary metabolomic fingerprint of T2D compared with non-T2D 37 
participants in the PREDIMED trial. The discriminant metabolite fingerprint was subjected to logistic 38 
regression analysis and ROC analyses to establish and to assess the multi-metabolite signature of 39 
T2D prevalence, respectively. Metabotypes associated with T2D were identified using the k-means 40 
algorithm.  41 
Results. – A total of 33 metabolites were significantly different (P < 0.05) between T2D and non-42 
T2D participants. The multi-metabolite signature of T2D comprised high levels of methylsuccinate, 43 
alanine, dimethylglycine and guanidoacetate, and reduced levels of glutamine, methylguanidine, 3-44 
hydro- xymandelate and hippurate, and had a 96.4% AUC, which was higher than the metabolites on 45 
their own and glucose. Amino-acid and carbohydrate metabolism were the main metabolic alterations 46 
in T2D, and various metabotypes were identified in the studied population. Among T2D participants, 47 
those with a metabotype of higher levels of phenylalanine, phenylacetylglutamine, p-cresol and 48 
acetoacetate had significantly higher levels of plasma glucose.  49 
Conclusion. – The multi-metabolite signature of T2D highlights the altered metabolic fingerprint 50 
associated mainly with amino-acid, carbohydrate and microbiota metabolism. Metabotypes identified 51 
in this patient population could be related to higher risk of long-term cardiovascular events and 52 
therefore require further studies. Metabolomics is a useful tool for elucidating the metabolic 53 
complexity and interindividual variation in T2D towards the development of stratified precision 54 
nutrition and medicine. Trial registration at www.controlled-trials.com: ISRCTN35739639. 55 
 56 
Introduction  57 
Type 2 diabetes (T2D) encompasses individuals who have hyperglycaemia resulting from defects in 58 
insulin secretion, insulin action or both [1]. Moreover, hyperglycaemia and insulin resistance are risk 59 
factors for cardiovascular disease (CVD) [2]. Besides an understanding of the pathophysiology of 60 
T2D, the identification of individuals at high risk, as well as knowledge of the metabolic alterations 61 
produced in patients with T2D, are crucial for preventative and disease management strategies. In 62 
recent years, progress in the development of biomarkers for T2D has been achieved due to advances 63 
in the emerging ‘-omics’ technologies, including metabolomics [3]. Successful applications of 64 
metabolomics in T2D research include the discovery of biomarkers for diagnoses and prognoses, 65 
altered metabolic pathways and drug mechanisms of action [4]. Currently, of the high-throughput 66 
analytical techniques, high-performance liquid chromatography–mass spectrometry (HPLC–MS) and 67 
proton nuclear magnetic resonance (1H-NMR) spectroscopy are those most widely employed in 68 
metabolomics for the study of diabetes, mostly due to their advantages in the analysis and 69 
identification of a broad range of metabolites in biofluids [3,4]. Furthermore, 1H-NMR is frequently 70 
used in non-targeted metabolomic approaches to profile metabolites in studies comparing T2D and 71 
non-T2D populations, as well as for elucidation and confirmation of the metabolic pathways altered 72 
as a consequence of T2D [3,5,6]. In recent years, several accurate prediction models have been 73 
constructed including variables such as age, gender and lifestyle factors [7], and some recent-omics 74 
technologies have the potential to serve as accurate analytical techniques for discovering novel 75 
biomarkers that could be involved in predictive models of T2D [4]. However, it should be pointed 76 
out that these models have mainly been tested with plasma samples, although a few have used urine 77 
samples and have also compared healthy vs T2D subjects. Thus, the use of these models in 78 
metabolomics is essential for identifying molecular signatures and phenotypic variations to improve 79 
prediction of disease risk and to better manage patients’ care and outcomes [8]. Recently, the term 80 
‘stratified medicine’ has emerged, based on the concept that some groups of individuals should be 81 
treated differently from others due to intervariability [8]. This inter-variability can be characterized 82 
by metabolomics through the study of metabolic phenotypes, or metabotypes, as the starting point for 83 
future stratified medicine programmes and lifestyle interventions [9]. In fact, patterns of variation or 84 
metabotypes have already been previously used in diabetes datasets to separate controls from patients 85 
[10] or healthy from diseased groups [11], as well as for studying metabolomic differences among 86 
clinical phenotypes [12] and developing strategies for delivery of dietary advice [11,13]. In the 87 
present study, the aim was to characterize the urinary metabolomic fingerprint and multi-metabolite 88 
signature associat-ed with T2D prevalence in the Prevention with Mediterranean Diet (PREDIMED) 89 
study population, using a 1H-NMR-based, non-targeted metabolomic approach and classifying the 90 
population into metabolic phenotypes (metabotypes) in relation to T2D.  91 
Methods  92 
Study population  93 
The PREDIMED was a parallel-group, single-blind, multicentre, randomized controlled 5-year 94 
clinical trial aimed at assessing the effects of the Mediterranean diet on CVD primary prevention 95 
[14]. Full details of the study design and protocol have been published elsewhere (www.predimed.es) 96 
[15]. Briefly, the parti-cipants were men (55–80 years of age) and women (60–80 years of age) with 97 
T2D and/or at least three of the following cardiovascular risk factors: hypertension; overweight [body 98 
mass index (BMI) > 25 kg/m2]; current smoker; low-density lipoprotein (LDL) cholesterol >4.14 99 
mmol/L; high-density lipoprotein (HDL) cholesterol <1.03 mmol/L; and a family history of 100 
premature CVD. The trial was registered at www.controlled-trials.com as ISRCTN35739639. The 101 
present PREDIMED substudy used data collected from 154 consecutive participants from two centres 102 
(Hospital Clinic of Barcelona and University of Valencia) where urinary metabolome was determined 103 
using the 1H-NMR approach at baseline. Of these 154 participants, 85 were T2D patients and 69 104 
were non-T2D subjects. The former were diagnosed as previously reported [14,16], and all 105 
participants were free of diabetic nephropathy. The institutional review boards of the two centres 106 
approved the study protocols, and written informed consent was given by all participants.  107 
Urine collection and measurements  108 
Spot urine samples were collected at baseline and immediately stored at -80ºC until analysis. Trained 109 
personnel performed the anthropometric and blood-pressure measurements. Validated questionnaires 110 
were employed to record physical activity, lifestyle, disease history and medication use [15].  111 
Metabolomic analysis: 1H-NMR sample preparation, data acquisition and processing  112 
Urine samples were thawed at 4º C and gently vortexed before metabolomic analysis, using a 113 
procedure based on a previously published methodology [17]. Briefly, 300 mL of urine were diluted 114 
in 200 mL of H2O/D2O (8:2 ratio) and mixed with an internal standard solution [0.1% chemical-shift 115 
reference 3-(trimethylsi-lyl)propionic-2,2,3,3-d4 acid sodium salt (TSP), 2 mM of sodium azide 116 
(NaN3) and 1.5 M of KH2PO4 in 99% deuterated water (D2O)]; the pH was set at 7.0 with a KOD 117 
solution. The 1H-NMR experiments were conducted using a 500-MHz spectrometer (Varian INOVA; 118 
Varian Medical Systems, Palo Alto, CA, USA), with presaturation of water resonance using a nuclear 119 
Overhauser enhancement (NOESY)-presat pulse sequence. Internal tempera-ture was kept constant 120 
at 298 K during acquisition. Spectra were acquired by collecting 128 scans at 32-K datapoints with a 121 
spectral width of 14 ppm, acquisition time of 2 s, relaxation delay of 5 s and mixing time of 100 ms. 122 
For spectral processing, the free induction decay (FID) was multiplied by an exponential function 123 
corres-ponding to a 0.3-Hz line broadening before Fourier transformation. All spectra were phased, 124 
baseline-corrected and referenced to TSP (d 0.0) using TopSpin version 3.2 software (Bruker BioSpin 125 
GmbH, Rheinstetten, Germany). The spectral data were processed, using an intelligent bucketing 126 
algorithm, in domains of 0.005 ppm [17] and integrated using ACD/NMR Processor 12.0 software 127 
(Advanced Chemistry Development, Inc., Toronto, ON, Canada). The spectral region 4.75–5.00 ppm 128 
was excluded from the dataset to avoid spectral interference from residual water.  129 
Statistical analysis  130 
A dataset containing integrals of NMR spectra was imported into MetaboAnalyst 3.0, a web-based 131 
platform for extensive analysis of metabolomic data [18], filtered using interquantile range (IQR) and 132 
row-wise-normalized by the sum of the spectral intensities. The normalized dataset was then imported 133 
into SIMCA-P+ 13.0 (Umetrics, Umea , Sweden) before being log-transformed and range-scaled 134 
prior to performing a principal component analysis to explore data distribution [17]. To reduce 135 
variability not associated with T2D classification, orthogonal signal correction (OSC) was applied to 136 
the dataset followed by partial least squares discriminant analysis (PLS-DA) to determine differences 137 
in metabolite profiling between the T2D and non-T2D groups. The predictive ability of the OSC–138 
PLS-DA models was then evaluated: one-third of the samples (validation set) were randomly 139 
removed from the whole dataset (training set), and the OSC–PLS-DA models calculated. This 140 
procedure was repeated five times, and was used to evaluate the ability of the models to classify 141 
prediction sets, and to calculate quality parameters of the method and the misclassification table. 142 
Quality and validation of the resultant OSC–PLS-DA models were assessed through R2Y(cum) and 143 
Q2(cum) parameters (calculated by seven-round internal data cross-validation using the default 144 
algorithm provided by the SIMCA-P+ 13.0 software), as well as by a permutation test (n = 200). 145 
Discriminant features between T2D patients and non- T2D subjects were identified from their 146 
variable importance in projection (VIP) values >1.0, a generally accepted threshold in metabolomic 147 
studies [17], with the VIP-sd(VIP) parameter also included as an additional quality parameter of the 148 
method. To eliminate the confusing effect of waist circumference, a general-ized linear model was 149 
applied, using the metabolic signature as an independent variable and T2D as a dependent variable, 150 
and adjusted by waist cirumference. Characteristics between participants were compared by apply-151 
ing Student’s t test and the chi-squared test for continuous and qualitative variables, respectively. 152 
Differences in metabolites between the T2D and non-T2D groups were tested using Student’s t test 153 
with a Benjamini–Hochberg procedure for adjusting P values. The significance level was set at P < 154 
0.05. Univariate analyses and generalized linear models were performed using IBM SPSS version 21 155 
software (IBM Corp., Armonk, NY, USA).  156 
Metabolite identification  157 
Identification of metabolites was achieved using the Chenomx NMR Suite 7.6 Profiler (Chenomx 158 
Inc, Edmonton, AB, Canada). In addition, NMR spectral libraries were consulted in databases such 159 
as the Human Metabolome Database [19] and Biological Magnetic Resonance Data Bank [20], 160 
together with the currently available literature on NMR-based metabolomics [4,17].  161 
Metabolic pathway analysis  162 
Identified metabolites were submitted to the Pathway Analysis and Network Analysis modules in 163 
MetaboAnalyst 3.0 [18] and MetaCoreTM (GeneGo, Inc., St. Joseph, MI, USA), respectively, to 164 
undergo analyses of metabolic pathways and biological inter-pretations of metabolites related to T2D. 165 
Multi-metabolite signature model for T2D prevalence  166 
The results obtained by OSC–PLS-DA analysis were subjected to forward conditional stepwise 167 
logistic regression analysis to design a multi-metabolite signature model of T2D prevalence. The 168 
prediction model was applied to a training set (two-thirds of participants) and subsequently validated 169 
against a validation set (one-third of participants). Quality of the models was evaluated by calculating 170 
the sensitivity, specificity and area under the receiver operating characteristic curves (AUROCs). 171 
Urinary glucose was not included in this analysis due to the high AUROCs. The optimal cut-off for 172 
calculating sensitivity and specificity was determined as the minimum distance to the top left-hand 173 
corner [21]. Significance was set at P < 0.05. IBM SPSS version 21 statistical software (IBM Corp) 174 
was used to perform the logistic regression and ROC analyses.  175 
Metabolic phenotypes by k-means algorithm  176 
Cluster analysis to identify metabolic phenotypes, or metabo-types, was performed using the k-means 177 
cluster algorithm in MetaboAnalyst 3.0 [12,22]. This generated two clusters in the diabetes patients 178 
and two clusters in the non-diabetic participants by taking as inputs the identified metabolites from 179 
the OSC–PLS-DA analysis and applying the k-means clustering algorithm [12]. After k-means 180 
analysis, the results for the four clusters were visualized using hierarchical clustering analysis.  181 
Results  182 
Subjects’ characteristics  183 
Our participants were 67 ± 6 years old and nearly one-third were male (Table 1). Also, 55% of 184 
participants had T2D and 47% were obese. They were divided according to T2D diagnosis, as 185 
previously reported [14,16]. Both groups (T2D and non-T2D) were well balanced in terms of 186 
demographic characteristics and other cardiovascular risk factors, such as blood pressure, plasma 187 
lipids, and antihypertensive and hypolipidaemic medications (P > 0.05). Otherwise, measures of waist 188 
circumference, plasma glucose and use of antidiabetic agents were significantly higher in the T2D 189 
patients, as expected.  190 
Profiles of discriminant metabolites of T2D biomarkers by 1H-NMR metabolomics  191 
OSC–PLS-DA models were applied to determine the profile of discriminant metabolites in T2D vs 192 
non-T2D subjects. These models resulted in one latent component with R2Y(cum) and Q2Y(cum) 193 
mean values of 0.829 and 0.679, respectively, indicating a good ability to classify individuals 194 
according to their T2D status. A permutation test (n = 200), with intercept R2Y and Q2Y mean values 195 
of 0.306 and -0.149, respectively, confirmed the validity of the model (Fig. S1; see supplementary 196 
materials associated with this article online). In addition, sensitivity, specificity and accuracy values 197 
were calculated from the OSC–PLS-DA models when samples were predicted (n = 5); these values 198 
were then included in a misclassification table (Table S1; see supplementary materials associated 199 
with this article online). Thus, t-test analyses among VIP > 1.0 identified 33 metabolites that were 200 
significantly different between the T2D and non-T2D participants (Table 2). Of these metabolites, 17 201 
were significantly increased in T2D patients compared with non-T2D subjects, while the remaining 202 
16 metabolites were decreased in T2D patients. In addition, the metabolic fingerprint associated with 203 
T2D was found to be significantly independent of waist circumference except for 4-deoxythreonic 204 
acid and citrate (P = 0.11), and 3- hydroxybutyrate (3HB) (P = 0.062; Table 2). Furthermore, no 205 
statistical differences were observed in levels of metabolites among T2D patients whether taking drug 206 
treatment or not (data not shown). A comprehensive analyses of the metabolic pathways (P and 207 
impact values) revealed that the carbohydrate and amino-acid pathways were the most altered among 208 
T2D patients (Fig. S2, Table S2; see supplementary materials associated with this article online). The 209 
metabolites involved in these pathways can be up- and downregulated (Fig. S3; see supplementary 210 
materials associated with this article online), and each metabolite is related to its own pathway (Table 211 
S3; see supplementary materials associated with this article online). 212 
Multi-metabolite signature of T2D prevalence  213 
The multi-metabolite signature for better discrimination of T2D prevalence included higher levels of 214 
methylsuccinate, alanine, dimethylglycine and guanidinoacetate, as well as lower levels of glutamine, 215 
methylguanidine, 3-hydroxymandelate and hippurate (Table S4; see supplementary materials 216 
associated with this article online). In the validation set, the specificity and sensitivity of the multi-217 
metabolite signature were 87.0% and 96.4%, respectively, while the AUROC was 96.4% (95% CI: 218 
92.0–100%; P < 0.001). However, the specificity, sensitivity and AUROC values of each individual 219 
metabolite as well as urinary glucose were lower than those of the multi-metabolite signature (Fig. 1, 220 
Table 3). 221 
Characterization of metabotypes 222 
Unsupervised analysis of k-means gave two metabotypes of diabetes participants and two 223 
metabotypes of non-diabetes participants (Table S5; see supplementary materials associated with this 224 
article online) from data for the 33 identified metabolites. After determining those four metabotypes, 225 
the results were visualized using hierarchical clustering (heatmap) analysis (Fig. 2), where 226 
samples/individuals are shown on the x-axis and metabolites are displayed on the y axis. Most of the 227 
up-and downregulated metabolites observed in the clusters were similar to those reported in Table 2 228 
for T2D and non-T2D participants except for four metabolites: acetoacetate (AA); p-cresol; 229 
phenylalanine; and phenylacetylglutamine (PAG). Levels of these four metabolites were significantly 230 
higher in clusters 2 and 3 than in clusters 1 and 4 (Fig. 2; P < 0.05) on stratifying the entire cohort, 231 
and were orthogonal for T2D. Thus, the two metabotypes of T2D (clusters 1 and 2) and two 232 
metabotypes of non-T2D (clusters 3 and 4) differed in these four metabolites. Cluster differences for 233 
subjects’ characteristics, concentrations of biochemical parameters and use of medication are 234 
presented in Table S5 (see supplementary materials associated with this article online). The main 235 
difference was that cluster 2, followed by cluster 1, had the highest plasma glucose levels, and both 236 
were significantly different from clusters 3 and 4 (P < 0.001). As expected, the use of insulin and oral 237 
antidiabetic agents was significantly different between T2D and non-T2D participants (P < 0.001), 238 
but did not differ between T2D metabotypes (P = 0.20).  239 
Discussion  240 
The present study found significant differences in the profile of 33 urinary metabolites between T2D 241 
and non-T2D participants, using a 1H-NMR-based, non-targeted metabolomic approach. 242 
Specifically, a model of eight metabolites was the multi-metabolite signature that discriminated 243 
between T2D and non-T2D after stepwise logistic regression analysis and AUROC evaluation. To 244 
the best of our knowledge, this was the first-ever study to use spot urine to determine the pathways 245 
altered in T2D in a free-living population, along with identifying a multi-metabolite signature of T2D 246 
prevalence while highlighting the key implied metabolites. This metabolomic clinical study also 247 
confirms the associated perturbations of amino-acid metabolism, with some amino acids being used 248 
as substrates for gluconeogenesis. In addition, the increased excretion of amino acids could indicate 249 
an increase in protein degradation [4]. This was observed in our present study, and corroborates other 250 
metabolomic studies showing enhanced excretion of the glucogenic amino-acids alanine [5,6] and 251 
phenylalanine [6] and derived metabolites such as guanidinoace-tate, and the decreased excretion of 252 
glutamine [6] and histidine [5]. Previously, it was found that levels of phenylalanine and glutamine 253 
were positively and inversely, respectively, associated with the risk of prediabetes and T2D [7,23]. 254 
In addition, deregulation of branched-chain amino-acid metabolites (valine, leucine, isoleucine) has 255 
also been associated with risk of diabetes and insulin resistance [7,23]. Indeed, such changes have 256 
been observed in urine through the increased excretion of metabolites such as 3-hydroxyisovalerate 257 
[24] and methylsuccinate from their degradation pathways, which may reflect greater isoleucine 258 
catabolism [25]. The present metabolomic clinical study has shown an increase in the glycolysis and 259 
gluconeogenesis pathways in the liver associated with increased excretion of metabolites, including 260 
lactate, glucose and pyruvate, as also observed in previous studies [4]. Increased amounts of some 261 
carboxylic acids, such as cis-aconitate, an intermediary in the tricarboxylic acid cycle, and 262 
dicarboxylic suberic acid, were observed in the urine of T2D patients. In fact, increased excretion of 263 
cis-aconitate reflects systemic stress caused by hyperglycaemia or local effects on tubular transport 264 
in the kidneys [5]. Metabolites related to methylamine metabolism, such as dimethylglycine and 265 
trime-thylamine N-oxide, are systemic breakdown products of choline [5] that, due to their 266 
osmoregulatory properties, may be linked to a hyperosmotic effect of glucose or indicate renal 267 
papillary dysfunction when found in high concentrations [26]. In our study, decreased urinary levels 268 
of creatinine and its metabolite methylguanidine [27] were also observed, which could be related to 269 
alterations of glomerular filtration rate (GFR) in T2D with a possible decrease of muscle mass [28], 270 
although our participants were free of nephropathy. However, in a recent report, lower creatinine 271 
excretion rates were associated with all-cause mortality in diabetes patients and in nephropathy [28]. 272 
Diabetes and obesity are lifestyle-related disorders that could cause an increased incidence of gut 273 
dysbiosis [29], which is directly related to alterations in gut microbial-related metabolites [30]. 274 
Indeed, the results of our study have shown a reduction in the excretion of well-known microbial 275 
metabolites, such as hippurate, PAG and p-cresol [29], as well as trigonelline and 3- 276 
hydroxymandelate. While PAG and p-cresol are related to protein putrefaction, hippurate is a 277 
breakdown product of polyphenol and fibre metabolism [9], and 3-hydroxymandelate is a metabolite 278 
of tyrosine [19]. Previous studies had observed that individuals with impaired glucose tolerance and 279 
patients with T2D have lower levels of hippurate and PAG [5]. Therefore, our study supports previous 280 
findings that a microbiota imbalance could be key in the pathogenesis of a diabetic state and that 281 
healthy diets and/or lifestyle patterns directed towards improving microbiota quality are essential for 282 
preventing advanced pathological states [31]. The present study identified two distinct metabotypes 283 
in T2D patients (clusters 1 and 2) and two in the non-T2D participants (clusters 3 and 4) using k-284 
means cluster analysis based on their identified metabolic profiles. It should be noted that the 285 
metabotype comprising higher levels of four metabolites (phenylalanine, PAG, p-cresol and AA) was 286 
found in the entire study population and was orthogonal for T2D. In particular, differences were 287 
observed in some parameters between clusters 1 and 2 (T2D patients) whereas no differences were 288 
noted between clusters 3 and 4 (non-T2D subjects). Although the increase in these metabolites were 289 
orthogonal for T2D, when the focus was on diabetes patients, those with higher levels of those four 290 
metabolites also had higher levels of plasma glucose, but with no differences in use of antidiabetic 291 
medications or in other characteristics. Thus, our hypothesis is that the T2D patients in cluster 2 could 292 
have had a greater lack of control over their disease which, in the long term, could have led to a 293 
greater number of complications such as myocardial infarction, stroke, heart failure and kidney 294 
disease [32]. Certainly, phenylalanine has been described as a marker of higher diabetes risk [7,23] 295 
and, furthermore, has also been used together with tyrosine and isoleucine to predict long-term future 296 
cardiovascular events, an increased disposition towards atheroscle- rosis and perhaps even inducible 297 
myocardial ischaemia [33]. In addition, phenylalanine has been identified as a biomarker associated 298 
with future cardiovascular events in meta-analyses [34]. PAG and p-cresol are metabolites of 299 
microbial origin [35]. PAG comes from the conversion of phenylalanine to phenylacetate by 300 
microbiota and its subsequent conjugation with glutamine [36]; and p-cresol, the most widely studied 301 
uraemic retention solute, is formed by microbial metabolism of tyrosine [36]. PAG has been 302 
described as a strong independent risk factor for mortality and CVD in patients with chronic kidney 303 
disease [35], while p-cresol has been described as a predictor of cardiovascular events independent 304 
of GFR in patients with mild-to-moderate kidney disease [37]. The fourth metabolite that differed 305 
between T2D clusters was the ketone body AA. This is generated from the ketogenic amino-acid 306 
lysine and may also be derived from b-oxidation of fatty acids. AA and 3HB are at a ratio of 1:1 in a 307 
physiological state, although 3HB increases its excretion in ketoacidosis [38]. Recent evidence has 308 
highlighted the association between elevated levels of ketone bodies and hyperglycaemia and T2D 309 
[39]. It is also worth noting that the T2D patients in clusters 1 and 2 had similar mean ratios of 310 
AA:3HB (1:2), whereas clusters 3 and 4 (non-T2D) had mean ratios of 1:1 (albeit not statistically 311 
significant). However, there were statistically significant differences (P = 0.007) between ratios in 312 
T2D (1:2) vs non- T2D (1:1) participants. Both hyperketonaemia and ketosis have been related to 313 
liver, brain and microvasculature complications, which can increase the risk of morbidity and 314 
mortality [40]. Therefore, the subjects in clusters 2 and 3 with increased levels of these four 315 
metabolites could have higher risks of CVD and other such events in future. Thus, further studies 316 
should now evaluate these metabolites in such populations in long-term studies. One limitation of our 317 
present study is that the panel of metabolites and the model used for the multi-metabolite signature 318 
imprinting of T2D were obtained from a high-cardiovascular-risk population, and so needs to be 319 
validated and replicated in other populations. In addition, the metabolite panel should also be tested 320 
in patients with different grades of T2D, including prediabetes states, to determine its limit values for 321 
prediction. Moreover, it would be of interest to evaluate whether our metabotypes are modified in 322 
states such as prediabetes. Another limitation of our study is that the microbial composition in these 323 
participants was unknown, thereby preventing any correlations with the identified metabolites. On 324 
the other hand, one strength of our study is that it reproduced of real-life conditions of the participants. 325 
In conclusion, the results of our cross-sectional study using a non-targeted 1H-NMR metabolomics 326 
approach reveal a multi-metabolite signature of T2D prevalence comprising eight metab-olites 327 
belonging to pathways related mainly to glucogenic and ketogenic amino acids, glycolysis and 328 
gluconeogenesis, carboxylic acid metabolism and changes in gut microbiota metabolism. This is also 329 
the first study to identify metabotypes in T2D, revealing that such patients have higher levels of 330 
phenylalanine, PAG, p-cresol and AA—metabolites related to higher risks of long-term cardio-331 
vascular events—and also higher levels of plasma glucose. Nevertheless, as they were orthogonal for 332 
T2D, further studies now need to evaluate their long-term effects. In addition, this study reinforces 333 
the use of metabolomics to discover and to evaluate the main metabolic pathways altered in T2D and 334 
the metabotypes of individuals. Thus, it would be highly useful to investigate T2D diagnosis and 335 
treatment to further support the development of stratified and precision medicine.  336 
Authors’ contributions  337 
M.U.-S., R.L., R.E., D.C., J.V.S., J.S.-S and C.A.-L. conceived and designed the study; M.U.-S., 338 
E.A.-A., R.L. and R.V.-F. performed the analyses; M.U.-S., E.A., R.L., R.V.-F., F.C., C.A.-L. and 339 
A.S.-P. analyzed the results; M.U.-S. and E.A. drafted the article. All of the authors critically revised 340 
the manuscript for important intellectual content. M.U.-S. and C.A.-L. are the guarantors of this work 341 
and, as such, had full access to all of the study data and take responsibility for the integrity of the data 342 
and accuracy of the data analysis.  343 
Disclosure of interest  344 
The authors declare that they have no competing interest.  345 
Acknowledgments  346 
This research was supported by Spanish national grants from the Ministry of Economy and 347 
Competitiveness (MINECO), and co-funded by FEDER (Fondo Europeo de Desarrollo Regional): 348 
AGL2009-13906-C02-01, as well as RYC-2011-09677, Associacio´ Catalana de Diabetis 349 
(ACD2015), CIBERFES, CIBER 06/03, CNIC-06, PI13/01172 Project (Plan Nacional de I+D+i 350 
2013–2016), PI11/ 02505 by ISCII-Subdireccio´n General de Evaluacio´n y Fomento de la 351 
Investigacio´ n, Fundacio la Marato TV3 (ref: 201608.10), and PROMETEO017/2017 (Generalitat 352 
Valenciana). We also thank the EU Joint Programming Initiative ‘A Healthy Diet for a Healthy Life’ 353 
on Biomarkers BioNHFOODBALL (PCIN-2014-133-MINECO-Spain) and the 2014SGR1566 354 
award from the Generalitat de Catalunya’s Agency AGAUR. M.U.-S. would like to thank the Ramo´n 355 
y Cajal programme from MINECO and Fondo Social Europeo. E.A.-A. would like to thank 356 
CONACYT (Mexico) for the PhD fellowship.  357 
Appendix A. Supplementary data 358 
Supplementary data associated with this article can be found, in the online version, at 359 
http://dx.doi.org/10.1016/j.diabet.2018. 02.006. 360 
References 361 
[1] American Diabetes Association. Classification and diagnosis of diabetes. Dia-betes Care 362 
2017;40:S11–24. 363 
[2] Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: 364 
pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J 2013;34:2436–43. 365 
[3] Adamski J. Key elements of metabolomics in the study of biomarkers of diabetes. Diabetologia 366 
2016;59:2497–502. 367 
[4] Urpi-Sarda M, Almanza-Aguilera E, Tulipani S, Tinahones F, Salas-Salvado J, Andres-Lacueva 368 
C. Metabolomics for biomarkers of Type 2 Diabetes Mellitus: advances and nutritional intervention 369 
trends. Curr Cardiovasc Risk Rep 2015;9:12. 370 
[5] Salek RM, Maguire ML, Bentley E, Rubtsov DV, Hough T, Cheeseman M, et al. A metabolomic 371 
comparison of urinary changes in type 2 diabetes in mouse, rat, and human. Physiol Genom 372 
2007;29:99–108. 373 
[6] van Doorn M, Vogels J, Tas A, van Hoogdalem EJ, Burggraaf J, Cohen A, et al. Evaluation of 374 
metabolite profiles as biomarkers for the pharmacological effects of thiazolidinediones in Type 2 375 
diabetes mellitus patients and healthy volun-teers. Br J Clin Pharm 2007;63:562–74. 376 
[7] Herder C, Kowall B, Tabak AG, Rathmann W. The potential of novel biomarkers to improve risk 377 
prediction of type 2 diabetes. Diabetologia 2014;57:16–29. 378 
[8] Pearson ER. Personalized medicine in diabetes: the role of ‘omics’ and bio-markers. Diabet Med 379 
2016;33:712–7. 380 
[9] Heinzmann SS, Merrifield CA, Rezzi S, Kochhar S, Lindon JC, Holmes E, et al. Stability and 381 
robustness of human metabolic phenotypes in response to sequential food challenges. J Proteome Res 382 
2012;11(2):643–55. 383 
[10] Cuperlovic-Culf M, Belacel N, Culf A, Chute I, Ouellette R, Burton I, et al. NMR metabolic 384 
analysis of samples using fuzzy k-means clustering. Magn Reson Chem 2009;47(Suppl 1):S96–104. 385 
[11] Nicholson JK, Holmes E, Kinross JM, Darzi AW, Takats Z, Lindon JC. Metabolic phenotyping 386 
in clinical and surgical environments. Nature 2012; 491:384–92. 387 
[12] Vazquez-Fresno R, Llorach R, Perera A, Mandal R, Feliz M, Tinahones FJ, et al. Clinical 388 
phenotype clustering in cardiovascular risk patients for the identifi-cation of responsive metabotypes 389 
after red wine polyphenol intake. J Nutr Biochem 2016;28:114–20. 390 
[13] O’Donovan C, Walsh M, Nugent A, McNulty B, Walton J, Flynn A, et al. Use of metabotyping 391 
for the delivery of personalised nutrition. Mol Nutr Food Res 2015;59:377–85. 392 
[14] Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F, et al. Primary prevention of 393 
cardiovascular disease with a Mediterranean diet. N Eng J Med 2013;368:1279–90. 394 
[15] Estruch R, Martinez-Gonzalez MA, Corella D, Salas-Salvado J, Ruiz-Gutierrez V, Covas MI, et 395 
al. Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial. Ann Intern 396 
Med 2006;145:1–11. 397 
[16] Salas-Salvado J, Bullo M, Estruch R, Ros E, Covas MI, Ibarrola-Jurado N, et al. Prevention of 398 
diabetes with Mediterranean diets: a subgroup analysis of a randomized trial. Ann Intern Med 399 
2014;160:1–10. 400 
[17] Vazquez-Fresno R, Llorach R, Urpi-Sarda M, Lupianez-Barbero A, Estruch R, Corella D, et al. 401 
Metabolomic pattern analysis after Mediterranean Diet Intervention in a Nondiabetic Population: a 402 
1- and 3-year follow-up in the PREDIMED study. J Proteome Res 2014;14:531–40. 403 
[18] Xia J, Mandal R, Sinelnikov IV, Broadhurst D, Wishart DS. MetaboAnalyst 2.0 – a 404 
comprehensive server for metabolomic data analysis. Nucleic Acids Res 2012;40(Web Server 405 
issue):W127–33. 406 
[19] Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y, et al. HMDB 3.0 – the human 407 
metabolome database in 2013. Nucleic Acids Res 2013;41(Database issue):D801–7. 408 
[20] Ulrich EL, Akutsu H, Doreleijers JF, Harano Y, Ioannidis YE, Lin J, et al. BioMagResBank. 409 
Nucleic Acids Res 2008;36(Database issue):D402–8. 410 
[21] Garcia-Aloy M, Llorach R, Urpi-Sarda M, Tulipani S, Estruch R, Martinez- Gonzalez MA, et 411 
al. Novel multimetabolite prediction of walnut consumption by a urinary biomarker model in a free-412 
living population: the PREDIMED study. J Proteome Res 2014;13:3476–83. 413 
[22] Gawlik A, Shmoish M, Hartmann MF, Malecka-Tendera E, Wudy SA, Hochberg Z. Steroid 414 
metabolomic disease signature of nonsyndromic childhood obesity. J Clin Endocrinol Metab 415 
2016;101:4329–37. 416 
[23] Guasch-Ferre M, Hruby A, Toledo E, Clish CB, Martinez-Gonzalez MA, Salas- Salvado J, et al. 417 
Metabolomics in prediabetes and diabetes: a systematic review and meta-analysis. Diabetes Care 418 
2016;39:833–46. 419 
[24] Kanehisa M, Goto S, Sato Y, Kawashima M, Furumichi M, Tanabe M. Data, information, 420 
knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res 2014;42(Database 421 
issue):D199–205. 422 
[25] Nowaczyk MJ, Lehotay DC, Platt BA, Fisher L, Tan R, Phillips H, et al. Ethylma-lonic and 423 
methylsuccinic aciduria in ethylmalonic encephalopathy arise from abnormal isoleucine metabolism. 424 
Metabolism 1998;47:836–9. 425 
[26] Guan M, Xie L, Diao C, Wang N, Hu W, Zheng Y, et al. Systemic perturbations of key 426 
metabolites in diabetic rats during the evolution of diabetes studied by urine metabonomics. PLoS 427 
ONE 2013;8(4):e60409. 428 
[27] Ienaga K, Hum Park C, Yokozawa T. Daily hydroxyl radical scavenging capacity of mammals. 429 
Drug Discov Ther 2014;8(2):71–5. 430 
[28] Sinkeler SJ, Kwakernaak AJ, Bakker SJ, Shahinfar S, Esmatjes E, de Zeeuw D, et al. Creatinine 431 
excretion rate and mortality in type 2 diabetes and nephrop-athy. Diabetes care 2013;36(6):1489–94. 432 
[29] Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, et al. Host-gut microbiota 433 
metabolic interactions. Science 2012;336(6086):1262–7. 434 
[30] Herrema HRGIJ, Nieuwdorp M. Emerging role of intestinal microbiota and microbial 435 
metabolites in metabolic control. Diabetologia 2017;60:613–7. 436 
[31] Blandino G, Inturri R, Lazzara F, Di Rosa M, Malaguarnera L. Impact of gut microbiota on 437 
diabetes mellitus. Diabetes Metab 2016;42:303–15. 438 
[32] Monnier L, Colette C. Postprandial and basal hyperglycaemia in type 2 diabe-tes: contributions 439 
to overall glucose exposure and diabetic complications. Diabetes Metab 2015;41(6 Suppl 1). 6S9–440 
6S15. 441 
[33] Magnusson M, Lewis GD, Ericson U, Orho-Melander M, Hedblad B, Engstrom G, et al. A 442 
diabetes-predictive amino acid score and future cardiovascular disease. Eur Heart J 2013;34:1982–9. 443 
[34] Wurtz P, Havulinna AS, Soininen P, Tynkkynen T, Prieto-Merino D, Tillin T, et al. Metabolite 444 
profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. Circulation 445 
2015;131:774–85. 446 
[35] Poesen R, Claes K, Evenepoel P, de Loor H, Augustijns P, Kuypers D, et al. Microbiota-derived 447 
phenylacetylglutamine associates with overall mortality and cardiovascular disease in patients with 448 
CKD. J Am Soc Nephrol 2016; 27:3479–87. 449 
[36] Swann JR, Spagou K, Lewis M, Nicholson JK, Glei DA, Seeman TE, et al. Microbial-450 
mammalian cometabolites dominate the age-associated urinary metabolic phenotype in Taiwanese 451 
and American populations. J Proteome Res 2013;12:3166–80. 452 
[37] Meijers BK, Claes K, Bammens B, de Loor H, Viaene L, Verbeke K, et al. p-Cresol and 453 
cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol 2010;5:1182–9. 454 
[38] Sheikh-Ali M, Karon BS, Basu A, Kudva YC, Muller LA, Xu J, et al. Can serum beta-455 
hydroxybutyrate be used to diagnose diabetic ketoacidosis? Diabetes care 2008;31:643–7. 456 
[39] Mahendran Y, Vangipurapu J, Cederberg H, Stancakova A, Pihlajamaki J, Soininen P, et al. 457 
Association of ketone body levels with hyperglycemia and type 2 diabetes in 9,398 Finnish men. 458 
Diabetes 2013;62:3618–26. 459 
[40] Kanikarla-Marie P, Jain SK. Hyperketonemia and ketosis increase the risk of complications in 460 










  471 
TABLES 
 
 
  
 
 
 
 
